New Technologies for Assessing and Predicting Risk: Application of Bioinformatics
Chair: Janet Woodcock, M.D., Center for Drug Evaluation & Research (CDER), FDA

• Development of a Toxicoinformatics Integrated System at NCTR
  Weida Tong, Ph.D., NCTR
  
  
• Serum Proteomic Pattern Diagnostics Using Artificial Intelligence Based Bioinformatics
  Emanuel Petricoin, Ph.D., Center for Biologics Evaluation & Research (CBER), FDA
  
  
• An Integration of Genomic, Proteomic, and Metabonomic Approaches To Better Evaluate Drug-Associated Cardiovascular Risks
  Frank Sistare, Ph.D., CDER, FDA
  
  
• Incorporation of Toxicogenomics into Mechanistic and Predictive Toxicology: Analysis of the Effects of Ethynyl Estradiol on Uterine Gene Expression
  Timothy Zacharewski, Ph.D., Michigan State University

Microbial Risk Balance: Assessing & Minimizing the Risk
Chair: David G. White, Ph.D., Center for Veterinary Medicine (CVM), FDA

• Application of Risk Assessment to Food Safety Problems
  Sherri B. Dennis, Ph.D., Center for Food Safety & Applied Nutrition (CFSAN), FDA
  
  
• Risk Assessment: Emerging Infectious Agents and Biologics
  Steven Anderson, Ph.D., M.P.P., CBER, FDA
  
  
• Vibrio spp. Risk Assessments
  Marianne Miliotis, Ph.D., CFSAN, FDA
  
  
• Modeling of Public Health Impact of Antibiotic Use in Agricultural and Human Clinical Settings: Smoking Gun vs. Holy Grail
  Glenn Morris, M.D., M.P.H., University of Maryland

Risk Assessment in Specific Subpopulations
Chair: Lawrence Lesko, Ph.D., CDER, FDA

• Critically Ill/Injured Patients as a Sensitive Subpopulation
  Ron Brown, M.S., D.A.B.T., Center for Devices & Radiological Health, (CDRH), FDA
  
  
• Subpopulation Based Model for Cryptosporidium Outbreaks
  Angelo Turturro, Ph.D., D.A.B.T., NCTR, FDA
  
  
• A Case Study in Subpopulation Risk Management
  Julie Beitz, M.D., CDER, FDA
  
  
• Environmental Health & Safety Risks to Children
  Carole A. Kimmel, Ph.D., Environmental Protection Agency

Defining Cancer Risk
Chair: Mary Bartholomew, Ph.D., CVM, FDA

• Thresholds, Risk Assessment, and Setting the Limits of Regulation
  Mitchell Cheeseman, Ph.D., CFSAN, FDA
  
  
• Using Computational Toxicology to Screen Chemicals for Carcinogenic Potential
  Joseph F. Contrera, Ph.D., CDER, FDA
  
  
• Relevance of Model Somatic Mutation Systems to Humans
  Richard J. Albertini, Ph.D., University of Vermont (invited)
  
  
• Unified Approach for Cancer and Non-cancer Risk Assessment
  Ralph Kodell, Ph.D., NCTR, FDA

Host Responses to Medical Interventions
Chair: Patrick McDermott, Ph.D., CVM, FDA

• Protective Innate Immune Responses Elicited by CpG Nucleotides
  Dennis Klinman, M.D., Ph.D., CBER, FDA
  
  
• Replacement Heart Valve-Related Pathology: In Vivo Preclinical Studies
  Stephen L. Hilbert, M.D., Ph.D., CDRH, FDA
  
  
• Antimicrobial Resistance as it Relates to Food Animal Production
  David G. White, Ph.D., CVM, FDA
  
  
• PET Imaging & Pharmacokinetics
  Jerry Collins, Ph.D., CDER, FDA

Applications of Edge of the Wedge Technology
Chair: Marwood Ediger, Ph.D., CDRH, FDA

• Progress Toward the Development of a Heat-Driven Process for Oligonucleotide Synthesis on Microarrays
  Serge Beaucage, Ph.D., CBER, FDA
  
  
• Evaluating Genotoxic Risk Using Tk Knockout Mouse Model
  V.N. Dobrovolsky, Ph.D., NCTR, FDA
  
  
• Blood substitutes: Can We Tame Hemoglobin?
  Abdu Alayash, Ph.D., CBER, FDA
  
  
• Application of Proteomics Based Analytical Tools to Food Safety Concerns
  Steven Musser, Ph.D., CFSAN, FDA

Toxicology: Expected & Unexpected Toxins & Toxicity
Chair: Renate Reimschuessel, V.M.D., Ph.D., CVM, FDA

• Multiresidue Screening for Pesticides in Food
  Frank J. Shenck, M.S., ORA, FDA
  
  
• Use of Biological Modeling in Risk Assessment
  Hoan-My Do Luu, M.S., CDRH, FDA
  
  
• Assessment of Neurotoxicity: Application of Neuroimaging Techniques
  William Slikker, Ph.D., NCTR, FDA
  
  
• The Role of Pharmacokinetics & Exposure-Response in Assessing Risk-Benefit of New Drugs
  Shiew-Mei Huang, Ph.D., CDER, FDA

Cancer : Origins, Diagnosis, Treatment and Prevention
Chair: Kathryn Zoon, Ph.D., CBER, FDA

• Cytokine Receptors as Targets of Cancer Therapy
  Raj K. Puri, M.D., Ph.D., CBER, FDA
  
  
• Cancer Susceptibility, Early Detection
  Luke Ratnasinghe, Ph.D., M.P.H., NCTR, FDA
  
  
• Effects of Exposure to Estrogens at Various Life Stages on Reproductive Endpoints and Cancer
  Kenneth B. DelClos, Ph.D., NCTR, FDA
  
  
• Diagnostic Imaging, Reader Variability, Computer Aids - and the Quest for the Holy Grail
  Robert F. Wagner, Ph.D., CDRH, FDA

• Workshop 1:  Level 2 - Room 201
  Committee for Advancement of FDA Science (CAFDAS) presents
  FDA Collaborative Grants Program
  
  
• Workshop 2:  Level 2 Room 202A
  Internet 2
  
  
• Workshop 3:  Level 2 Room 202B
  Communication in Science
  
  
• Workshop 4:  Level 2 Room 204ABC
  Introduction to FDA

On the Scene: Detecting Biological and Security Risks
Co-chairs: David Feigal, M.D., M.P.H., CDRH, FDA and Douglas Anders, Ph.D., Federal Bureau of Investigation

• Evaluation of Handheld Anthrax Test Kits: Lessons Learned
  Richard Meyer, Ph.D., Centers for Disease Control
  
  
• Collaborative Efforts to Promote Diagnostic Platform Development
  Lt. Col. Debra Niemeyer, Ph.D., Department of Defense
  
  
• FDA's Role in Security Screening Systems: Radiation Risks, Privacy Laws, & Public Concern
  Orhan Suleiman, Ph.D., Office of the Commissioner (OC), FDA

Therapeutic & Prophylactic Strategies for Countering Terrorism
Co-chairs: Steven K. Galson, M.D., M.P.H., CDER and Andrea Meyerhoff, M.D., OC, FDA

• Drug Efficacy & Off-Label Use
  Diane Murphy, M.D., CDER, FDA
  
  
• Emerging & Re-Emerging Biologic Issues
  Lauren Iaconno- Connors, Ph.D., CBER, FDA
  
  
• Civilian BioDefense Strategies
  Tara O'Toole, M.D., Johns Hopkins University

Bioterrorism Risk and the Nation's Food Supply - How Must We Respond
Co-chairs: Ellen Morrison, OC, FDA and William Krueger, Minnesota Department of Agriculture

• FDA's Efforts on Food Safety & Security
  Joe Levitt, Esq, CFSAN, FDA
  
  
• The NIH Response to the Threat of Bioterrorism
  Leigh A. Sawyer, D.V.M., M.P.H, DACVPM, National Institutes of Health
  
  
• The Food Industry's Response to Ensuring Food Security and Safety
  Rhona Applebaum, Ph.D., National Food Processors Association

Emerging Issues in Risk Communication
Co-chairs: Linda A. Skladany, Esq, OC, FDA & Kevin Keane, DHHS

• Public Participation in Risk Communication
  Ned Growth, Consumers Union
  
  
• Communicating Sound Science Policy in a Chaotic World
  Stephen F. Sundlof, D.V.M., Ph.D., CVM, FDA
  
  
• FDA & the Media: Communicating Risk to the Public
  Lauren Neergard, Associated Press